← Leaderboards
Douglas L Feinstein
Jesse Brown Va Medical Center
$9,279,757
Attributed
$9,279,757
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $783.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,279,757 · 8
VA$0 · 4
By mechanism
U01$6,269,787 · 2
R01$2,608,266 · 2
P01$364,204 · 1
R13$37,500 · 2
P41$0 · 1
I21$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Jesse Brown Va Medical Center
Same institution · by research overlap
- Waddah A Alrefai$4,247,097
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsInflammationSymptomsBrainFda ApprovedOligodendrogliaProductionExperimental Autoimmune EncephalomyelitisRattusNeuronsProteinsNeurogliaPreventFamilyInflammatory ResponseMultiple Sclerosis PatientCellsVeteransChronicAlzheimer&AposMultiple SclerosisExposure ToRodenticidesGenes
Grant awards (47)
Optimization of Bile Sequestrants to Treat Superwarfarin Poisoning$643,894
U01 · FY2025 · NS · contact PI
Accelerating remyelination using lanthionine ketimine derivatives$0
I01 · FY2025 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Optimization of Bile Sequestrants to Treat Superwarfarin Poisoning$658,894
U01 · FY2024 · NS · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Accelerating remyelination using lanthionine ketimine derivatives$0
I01 · FY2024 · VA · contact PI
Characterization of the oral microbiome of patients with Multiple Sclerosis$0
I21 · FY2024 · VA · contact PI
Optimization of Bile Sequestrants to Treat Superwarfarin Poisoning$643,894
U01 · FY2023 · NS · contact PI
Characterization of the oral microbiome of patients with Multiple Sclerosis$0
I21 · FY2023 · VA · contact PI
Accelerating remyelination using lanthionine ketimine derivatives$0
I01 · FY2023 · VA · contact PI
Liver Kinase B1, a genetic risk factor for multiple sclerosis$0
I01 · FY2023 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2023 · VA · contact PI
Optimization of Bile Sequestrants to Treat Superwarfarin Poisoning$673,844
U01 · FY2022 · NS · contact PI
Liver Kinase B1, a genetic risk factor for multiple sclerosis$0
I01 · FY2022 · VA · contact PI
Accelerating remyelination using lanthionine ketimine derivatives$0
I01 · FY2022 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2022 · VA · contact PI
Liver Kinase B1, a genetic risk factor for multiple sclerosis$0
I01 · FY2021 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2021 · VA · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2020 · VA · contact PI
Liver Kinase B1, a genetic risk factor for multiple sclerosis$0
I01 · FY2020 · VA · contact PI
Identification and characterization of a novel risk factor for MS$0
I01 · FY2019 · VA · contact PI
Intralipid: A novel frontline countermeasure for brodifacoum poisoning$159,900
U01 · FY2018 · NS · contact PI
Identification and characterization of a novel risk factor for MS$0
I01 · FY2018 · VA · contact PI
Intralipid: A novel frontline countermeasure for brodifacoum poisoning$672,139
U01 · FY2017 · NS · contact PI
Identification and characterization of a novel risk factor for MS$0
I01 · FY2017 · VA · contact PI
Intralipid: A novel frontline countermeasure for brodifacoum poisoning$671,901
U01 · FY2016 · NS · contact PI
Identification and characterization of a novel risk factor for MS$0
I01 · FY2016 · VA · contact PI
Intralipid: A novel frontline countermeasure for brodifacoum poisoning$668,481
U01 · FY2015 · NS · contact PI
Intralipid: A novel frontline countermeasure for brodifacoum poisoning$663,472
U01 · FY2014 · NS · contact PI
Intralipid: A novel frontline countermeasure for brodifacoum poisoning$120,329
U01 · FY2014 · NS · contact PI
Intralipid: A novel frontline countermeasure for brodifacoum poisoning$693,039
U01 · FY2013 · NS · contact PI
American Society for Neurochemistry 42nd Annual Meeting$20,000
R13 · FY2011 · NS · contact PI
Treatment of Demyelinating Disease with HSP90 Inhibitors$302,104
R01 · FY2010 · NS · contact PI
41st Annual Meeting of American Society for Neurochemistry$17,500
R13 · FY2010 · NS · contact PI
Treatment of Demyelinating Disease with HSP90 Inhibitors$305,156
R01 · FY2009 · NS · contact PI
Treatment of Demyelinating Disease with HSP90 Inhibitors$305,156
R01 · FY2008 · NS · contact PI
Treatment of Demyelinating Disease with HSP90 Inhibitors$339,063
R01 · FY2007 · NS · contact PI
The role of I-kappaB in control of glial inflammation$377,473
R01 · FY2006 · NS · contact PI
The role of I-kappaB in control of glial inflammation$296,153
R01 · FY2005 · NS
The role of I-kappaB in control of glial inflammation$67,803
R01 · FY2005 · NS
The role of I-kappaB in control of glial inflammation$296,153
R01 · FY2004 · NS
The role of I-kappaB in control of glial inflammation$319,205
R01 · FY2003 · NS
GENE EXPRESSION IN RAT GLIAL CELLS$0
P41 · FY2002 · RR
GENE EXPRESSION IN RAT GLIAL CELLS$0
P41 · FY2002 · RR
CORE--NEUROCHEMISTRY/MOLECULAR BIOLOGY$117,022
P01 · FY2001 · HL
GENE EXPRESSION IN RAT GLIAL CELLS$0
P41 · FY2001 · RR
CORE--NEUROCHEMISTRY/MOLECULAR BIOLOGY$247,182
P01 · FY2000 · HL